Pipeline & Programs | Nevakar, Inc

Nevakar’s business model focuses on repositioning and repurposing existing drugs to address unmet needs that are patient and health care system centric. Nevakar’s unique ideation and pipeline development process allows us to accelerate discovery, development and commercial launch.

We call this novel approach NuPharming^TM.

portfolio

Nevakar focuses on two significant markets:

Ophthalmics

Ophthalmics is a large and growing market in which refractive errors are a key driver.

Hospital Injectables

Hospital Injectables is another underserved market presenting significant patient and healthcare system value. Suboptimal products and delivery are key unmet needs in this market.

Global cost of correcting refractive errors estimated to be $2.8 trillion¹

4 billion people worldwide suffer from refractive errors²

Today, 2.5 billion people have myopia and the cost of uncorrected myopia is $244 billion³

There are currently no approved pharmacological interventions to treat refractive errors⁴

The global hospital injectables market is $624.5 billion⁵

313 million surgeries are performed in US each year⁶

There are 1.7 million US hospital-acquired infections leading to 99 thousand deaths annually⁷

Hospital costs in US for critically ill patients have doubled in the past decade to $108 billion⁸

Our Pipeline

Ophthalmic Products

Product CandidatesTherapeutic Area	Research	Preclinical	Phase I	Phase II	Phase III
NVK-002Atropine for Children with Myopia (US & Europe)	Research	Preclinical	Phase I	Phase II	Phase III
NVK-002Atropine for Children with Myopia (Asia)	Research	Preclinical	Phase I	Phase II	Phase III
NVK-029Refractive errors I	Research	Preclinical	Phase I	Phase II	Phase III
NVK-031Refractive errors II	Research	Preclinical	Phase I	Phase II	Phase III

Hospital Injectables

Product CandidatesTherapeutic Area	Research	Preclinical	Phase I	Phase II	Phase III
NVK-009Acute Pain	Research	Preclinical	Phase I	Phase II	Phase III
NVK-006Anti-infective	Research	Preclinical	Phase I	Phase II	Phase III

Critical Care Injectables

Product CandidatesTherapeutic Area	Research	Preclinical	Phase I	Phase II	Phase III
NVK-003Anesthesia	Research	Preclinical	Phase I	Phase II	Phase III
NVK-014Cardiovascular	Approved
NVK-004Cardiovascular	Research	Preclinical	Phase I	Phase II	Phase III
NVK-019Cardiovascular	Research	Preclinical	Phase I	Phase II	Phase III
NVK-005Oncology	Research	Preclinical	Phase I	Phase II	Phase III
NVK-025Cardiovascular	Research	Preclinical	Phase I	Phase II	Phase III
NVK-028Cardiovascular	Research	Preclinical	Phase I	Phase II	Phase III
NVK-030Gastrointestinal	Research	Preclinical	Phase I	Phase II	Phase III

Interested in becoming part of the team?

Interested in discussing potential partnerships?

References for Opthalmics:
1. Fricke TR, Holden BA, Wilson DA, Schlenther G, Naidoo KS, Resnikoff S, et al. Global cost of correcting vision impairment from uncorrected refractive error. Bull World Health Organ 2012;90:728-38. 2. Naidoo KS, Fricke TR, Frick KD, et al. Potential lost productivity resulting from the global burden of myopia: systematic review, meta-analysis, and modeling. Ophthalmology. 2019;126:338–46. 3. World Health Organization Bulletin, 2015;93:667. doi: http://dx.doi.org/10.2471/BLT.15.156844. 4. Fricke TR, Tahhan N, Resnikoff S, Papas E, Burnett A, Ho SM, Naduvilath T, Naidoo KS. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: Systematic Review, Meta-analysis, and Modelling. Ophthalmology. 2018 Oct;125(10):1492-1499. doi: 10.1016/j.ophtha.2018.04.013. Epub 2018 May 9. PMID: 29753495.https://www.marketsandmarkets.com/Market-Reports/injectable-drug-delivery-market-150.html

References for Hospital Injectables:
5. https://www.marketsandmarkets.com/Market-Reports/injectable-drug-delivery-market-150.html. 6. Gan TJ et al. Curr Med Res Opin. 2014;30(1):149-160 7.https://patientcarelink.org/improving-patient-care/healthcare-acquired-infections-hais/ 8. https://www.sccm.org/Communications/Critical-Care-Statistics.